MOG Proteins, Peptides, Antibodies & Kits

Myelin Oligodendrocyte Glycoprotein (MOG), a 26- to 28-kDa protein, is a member of the immunoglobulin superfamily. It is expressed exclusively in the central nervous system (CNS), specifically on the surface of myelinating oligodendrocytes and external lamellae of myelin sheath. Although MOG protein constitutes only 0.01-0.05% of the CNS myelin proteins, it was demonstrated that MOG protein is a crucial autoantigen for multiple sclerosis in humans and experimental autoimmune encephalomyelitis (EAE) in rodents and monkeys (1-6).

AnaSpec is pleased to be the first in the industry to provide a whole suite of reagents and assay kits for the advancement of MS research. This includes MOG proteins, peptides, and assay kits.

MOG Proteins

These proteins, with sequences corresponding to human, mouse and rat extracellular domain, together with a 6x His tag were expressed in E. coli and purified from urea denatured bacterial lysate. The molecular weight found in all 3 recombinant proteins was 14.23 kDa. These proteins were shown to induce EAE in either mouse (for the human and mouse rMOGs) or rat (for rat rMOG).

Recombinant MOG Protein


Catalog #

Recombinant human MOG NEW

100 µg

500 µg

1000 µg




Recombinant mouse MOG NEW

100 µg

500 µg

1000 µg




Recombinant rat MOG NEW

100 µg

500 µg

1000 µg




Figure 1. Western blots of MOG recombinant proteins for human (A), mouse (B) and rat (C).

MOG (35-55) and other MOG Peptide Fragments

AnaSpec's MOG (35-55) peptide from mouse and rat sequence (cat# 60130) was shown to induce anti-MOG (35-55) autoantibody production in C57BL/6 mice at 100% incidence (10/10); providing quantitative data that this peptide is suitable for in vivo anti-MOG (35-55) autoantibody study. A cysteine-containing MOG (35-55) peptide induced polyclonal anti-MOG (35-55) antibody production in rabbits with high specificity, high affinity, and high titer indicating its high purity, as well as suitability for use in peptide-coated ELISA and Western blot. This mouse/rat MOG (35-55) peptide was used as a coating peptide to develop the industry's first anti-MOG (35-55) ELISA kit for EAE study. The detection limit of the kit was determined to reach as low as 50 pg of anti-MOG (35-55) autoantibody in serum or cerebrospinal fluid. Lot to lot variability of the MOG (35-55) was found to be minimal.

SensoLyte® Anti-MOG IgG ELISA Assay Kits

The SensoLyte Anti-Human MOG (1-125) IgG Quantitation ELISA Kit, SensoLyte® Anti-Mouse MOG (1-125) and SensoLyte® Anti-Rat MOG (1-125) IgG ELISA assay kits are useful for determining the amount of anti-human MOG (1-125), anti-mouse MOG (1-125) and anti-rat MOG (1-125) antibodies, respectively. These kits, as well as the recombinant MOG (1-125) proteins are examples of innovative products from AnaSpec.

SensoLyte® Anti-Human MOG (1-125) Assay

SensoLyte® Anti-Mouse MOG (1-125) Assay

SensoLyte® Anti-Rat MOG (1-125) Assay






Human rMOG (1-125) precoated 12-strip plate

Mouse rMOG (1-125) precoated 12-strip plate

Rat rMOG (1-125) precoated 12-strip plate

Standard(s) Included

Mouse & Rat anti-human MOG (1-125) IgG standards

Anti-mouse MOG (1-125) IgG standard

Anti-rat MOG (1-125) IgG standard


Detects as low as 1 ng anti-human MOG (1-125)

Detects as low as 1 ng anti-mouse MOG (1-125)

Detects as low as 1 ng anti-rat MOG (1-125)

Assay Time

2-3 hours assay time at room temperature

Sample Concentration

0.5-1 μl of serum or cerebrospinal fluid


Colorimetric read-out at 450 nm absorbance

Broad Dynamic Range

8-500 ng IgG/ml serum (depending on colorimetric developing time)

The SensoLyte® Anti-MOG (35-55) IgG Quantitative ELISA kit is optimized to detect anti-MOG (35-55) mouse/rat IgG. Using strips pre-coated with MOG (35-55) peptide and pre-blocked with BSA, the amount of anti-MOG IgG in serum or cerebrospinal fluid can be determined by ELISA and the absorbance read at 450 nm.

SensoLyte® Anti - MOG(35 - 55) IgG Quantitative ELISA Kit (mouse/rat)


Related Products:

MBP Peptides
PLP Peptides


1. Linares, D. et al. Protein Expression and Purif. 34, 249 (2004).
2. Bettadapura, J. et al. J. Neurochem. 70, 1593 (1998).
3. Oliver, AR. et al J. Immunol. 171, 462 (2003).
4. Von Budingen, H-C. et al. J. Clin. Immunol. 21, 155 (2001).
5. Lyons, J-A. Eur. J. Immunol. 29, 3432 (1999).
6. Von Budingen, H-C. Eur. J. Immunol. 34, 2072 (2003 ).